 Tejas Patil
Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 25 | 2024 | 959 | 4.490 |
Why?
| | Lung Neoplasms | 27 | 2024 | 2159 | 3.280 |
Why?
| | Protein-Tyrosine Kinases | 7 | 2023 | 393 | 1.010 |
Why?
| | Proto-Oncogene Proteins | 7 | 2023 | 607 | 0.990 |
Why?
| | Mutation | 12 | 2024 | 3338 | 0.880 |
Why?
| | ErbB Receptors | 10 | 2024 | 554 | 0.800 |
Why?
| | Brain Neoplasms | 5 | 2023 | 966 | 0.780 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2020 | 1356 | 0.740 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2021 | 636 | 0.690 |
Why?
| | Receptor, ErbB-2 | 2 | 2019 | 300 | 0.610 |
Why?
| | Pleural Effusion, Malignant | 1 | 2016 | 8 | 0.530 |
Why?
| | Pleural Neoplasms | 1 | 2016 | 18 | 0.520 |
Why?
| | Peritoneal Neoplasms | 1 | 2016 | 54 | 0.500 |
Why?
| | Adenocarcinoma | 2 | 2018 | 787 | 0.490 |
Why?
| | Protein Kinase Inhibitors | 7 | 2023 | 784 | 0.470 |
Why?
| | Aniline Compounds | 3 | 2024 | 70 | 0.470 |
Why?
| | Acrylamides | 2 | 2024 | 42 | 0.420 |
Why?
| | Gene Rearrangement | 4 | 2022 | 135 | 0.360 |
Why?
| | Pyrimidines | 3 | 2024 | 374 | 0.350 |
Why?
| | Lung | 2 | 2018 | 3521 | 0.330 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 5 | 2023 | 228 | 0.330 |
Why?
| | Antineoplastic Agents | 4 | 2023 | 1875 | 0.320 |
Why?
| | Retrospective Studies | 14 | 2024 | 12521 | 0.300 |
Why?
| | Pyrazoles | 2 | 2021 | 361 | 0.280 |
Why?
| | Neoplasm Staging | 4 | 2019 | 1162 | 0.280 |
Why?
| | Middle Aged | 16 | 2024 | 26607 | 0.280 |
Why?
| | Survival Rate | 6 | 2020 | 1638 | 0.270 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2020 | 577 | 0.260 |
Why?
| | Central Nervous System | 3 | 2023 | 230 | 0.250 |
Why?
| | Humans | 30 | 2024 | 114050 | 0.250 |
Why?
| | Proto-Oncogene Proteins c-met | 2 | 2023 | 67 | 0.240 |
Why?
| | Aged, 80 and over | 4 | 2020 | 6307 | 0.230 |
Why?
| | Aged | 11 | 2024 | 18971 | 0.230 |
Why?
| | Proto-Oncogene Proteins c-ret | 2 | 2021 | 27 | 0.230 |
Why?
| | Oncogenes | 3 | 2022 | 104 | 0.220 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1032 | 0.220 |
Why?
| | Mesothelioma | 1 | 2023 | 31 | 0.210 |
Why?
| | Oncogene Addiction | 1 | 2023 | 5 | 0.210 |
Why?
| | Chemoradiotherapy | 1 | 2024 | 187 | 0.200 |
Why?
| | Female | 18 | 2024 | 59328 | 0.200 |
Why?
| | Acetonitriles | 1 | 2021 | 8 | 0.190 |
Why?
| | Pyridines | 2 | 2021 | 419 | 0.180 |
Why?
| | Circulating Tumor DNA | 1 | 2020 | 22 | 0.170 |
Why?
| | Lactams | 1 | 2019 | 18 | 0.170 |
Why?
| | Gene Amplification | 1 | 2019 | 95 | 0.160 |
Why?
| | Lactams, Macrocyclic | 1 | 2019 | 46 | 0.160 |
Why?
| | Male | 15 | 2024 | 55400 | 0.160 |
Why?
| | Tracheal Neoplasms | 1 | 2019 | 9 | 0.160 |
Why?
| | Aminopyridines | 1 | 2019 | 81 | 0.160 |
Why?
| | Piperazines | 1 | 2021 | 310 | 0.160 |
Why?
| | Genes, erbB-1 | 1 | 2018 | 17 | 0.160 |
Why?
| | Oncogene Proteins | 1 | 2018 | 53 | 0.150 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2018 | 67 | 0.150 |
Why?
| | Thromboembolism | 1 | 2018 | 92 | 0.150 |
Why?
| | Prognosis | 3 | 2020 | 3315 | 0.150 |
Why?
| | Disease-Free Survival | 2 | 2017 | 618 | 0.150 |
Why?
| | Computed Tomography Angiography | 1 | 2018 | 100 | 0.150 |
Why?
| | Antibodies, Monoclonal | 1 | 2024 | 1257 | 0.140 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 347 | 0.140 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 137 | 0.140 |
Why?
| | Biomarkers, Pharmacological | 1 | 2017 | 26 | 0.140 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 241 | 0.140 |
Why?
| | Smad4 Protein | 1 | 2017 | 34 | 0.140 |
Why?
| | Gene Deletion | 1 | 2018 | 356 | 0.140 |
Why?
| | Erlotinib Hydrochloride | 1 | 2017 | 64 | 0.140 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 152 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2023 | 850 | 0.140 |
Why?
| | Follow-Up Studies | 3 | 2020 | 4392 | 0.130 |
Why?
| | Adult | 6 | 2023 | 30377 | 0.130 |
Why?
| | Colorectal Neoplasms | 1 | 2021 | 592 | 0.120 |
Why?
| | Disease Progression | 2 | 2018 | 2371 | 0.120 |
Why?
| | Liver Neoplasms | 1 | 2018 | 504 | 0.120 |
Why?
| | Tomography, X-Ray Computed | 2 | 2022 | 2272 | 0.110 |
Why?
| | Incidence | 1 | 2018 | 2314 | 0.100 |
Why?
| | Smoking | 1 | 2018 | 1382 | 0.100 |
Why?
| | Quality of Life | 1 | 2022 | 2343 | 0.090 |
Why?
| | Biomarkers | 1 | 2017 | 3397 | 0.070 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 521 | 0.070 |
Why?
| | Consolidation Chemotherapy | 1 | 2024 | 9 | 0.060 |
Why?
| | Peritoneum | 1 | 2023 | 36 | 0.050 |
Why?
| | Young Adult | 1 | 2018 | 10446 | 0.050 |
Why?
| | Kelch-Like ECH-Associated Protein 1 | 1 | 2023 | 8 | 0.050 |
Why?
| | Platinum | 1 | 2023 | 38 | 0.050 |
Why?
| | Sequence Deletion | 1 | 2023 | 166 | 0.050 |
Why?
| | Taxoids | 1 | 2023 | 93 | 0.050 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2022 | 14 | 0.050 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2023 | 71 | 0.050 |
Why?
| | Exons | 1 | 2023 | 301 | 0.050 |
Why?
| | Indoles | 1 | 2024 | 300 | 0.050 |
Why?
| | Medical Oncology | 1 | 2023 | 229 | 0.050 |
Why?
| | Appendiceal Neoplasms | 1 | 2021 | 14 | 0.050 |
Why?
| | Neoadjuvant Therapy | 1 | 2023 | 305 | 0.050 |
Why?
| | Meningeal Neoplasms | 1 | 2021 | 86 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2022 | 224 | 0.040 |
Why?
| | Gene Fusion | 1 | 2018 | 18 | 0.040 |
Why?
| | Protein Conformation | 1 | 2021 | 803 | 0.040 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2017 | 15 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 193 | 0.030 |
Why?
| | Immunotherapy | 1 | 2020 | 473 | 0.030 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 191 | 0.030 |
Why?
| | Etoposide | 1 | 2017 | 149 | 0.030 |
Why?
| | Cranial Irradiation | 1 | 2017 | 66 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 813 | 0.030 |
Why?
| | Deoxycytidine | 1 | 2017 | 138 | 0.030 |
Why?
| | Genomics | 1 | 2020 | 631 | 0.030 |
Why?
| | Salvage Therapy | 1 | 2017 | 127 | 0.030 |
Why?
| | DNA Repair | 1 | 2017 | 184 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1206 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1422 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 594 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2017 | 445 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 660 | 0.030 |
Why?
| | Databases, Factual | 1 | 2019 | 1125 | 0.030 |
Why?
| | Mass Screening | 1 | 2020 | 979 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 926 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1117 | 0.030 |
Why?
| | Radiosurgery | 1 | 2017 | 299 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2023 | 3039 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1145 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 2764 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 5499 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2090 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 6077 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2023 | 9049 | 0.020 |
Why?
| | Signal Transduction | 1 | 2017 | 4501 | 0.010 |
Why?
| | United States | 1 | 2019 | 12137 | 0.010 |
Why?
|
|
Patil's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|